Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
27 08 2022
Historique:
received: 16 10 2021
revised: 12 02 2022
accepted: 04 03 2022
pubmed: 25 3 2022
medline: 31 8 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

Disability accrual in multiple sclerosis may occur as relapse-associated worsening or progression independent of relapse activity. The role of progression independent of relapse activity in early multiple sclerosis is yet to be established. The objective of this multicentre, observational, retrospective cohort study was to investigate the contribution of relapse-associated worsening and progression independent of relapse activity to confirmed disability accumulation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, assessed within one year from onset and with follow-up ≥5 years (n = 5169). Data were extracted from the Italian Multiple Sclerosis Register. Confirmed disability accumulation was defined by an increase in Expanded Disability Status Scale score confirmed at 6 months, and classified per temporal association with relapses. Factors associated with progression independent of relapse activity and relapse-associated worsening were assessed using multivariable Cox regression models. Over a follow-up period of 11.5 ± 5.5 years, progression independent of relapse activity occurred in 1427 (27.6%) and relapse-associated worsening in 922 (17.8%) patients. Progression independent of relapse activity was associated with older age at baseline [hazard ratio (HR) = 1.19; 95% confidence interval (CI) 1.13-1.25, P < 0.001], having a relapsing-remitting course at baseline (HR = 1.44; 95% CI 1.28-1.61, P < 0.001), longer disease duration at baseline (HR = 1.56; 95% CI 1.28-1.90, P < 0.001), lower Expanded Disability Status Scale at baseline (HR = 0.92; 95% CI 0.88-0.96, P < 0.001) and lower number of relapses before the event (HR = 0.76; 95% CI 0.73-0.80, P < 0.001). Relapse-associated worsening was associated with younger age at baseline (HR = 0.87; 95% CI 0.81-0.93, P < 0.001), having a relapsing-remitting course at baseline (HR = 1.55; 95% CI 1.35-1.79, P < 0.001), lower Expanded Disability Status Scale at baseline (HR = 0.94; 95% CI 0.89-0.99, P = 0.017) and a higher number of relapses before the event (HR = 1.04; 95% CI 1.01-1.07, P < 0.001). Longer exposure to disease-modifying drugs was associated with a lower risk of both progression independent of relapse activity and relapse-associated worsening (P < 0.001). This study provides evidence that in an early relapsing-onset multiple sclerosis cohort, progression independent of relapse activity was an important contributor to confirmed disability accumulation. Our findings indicate that insidious progression appears even in the earliest phases of the disease, suggesting that inflammation and neurodegeneration can represent a single disease continuum, in which age is one of the main determinants of disease phenomenology.

Identifiants

pubmed: 35325059
pii: 6553893
doi: 10.1093/brain/awac111
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2796-2805

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Emilio Portaccio (E)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.
Department of Neurology, IRCCS Fondazione Don Carlo Gnocchi, 50143 Florence, Italy.

Angelo Bellinvia (A)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.

Mattia Fonderico (M)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.

Luisa Pastò (L)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.

Lorenzo Razzolini (L)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.

Rocco Totaro (R)

Demyelinating Disease Center, San Salvatore Hospital, 67100 L'Aquila, Italy.

Daniele Spitaleri (D)

Department of Neurology, AORN San G. Moscati di Avellino, 83100 Avellino, Italy.

Alessandra Lugaresi (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, 40139 Bologna, Italy.
Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40138 Bologna, Italy.

Eleonora Cocco (E)

Department of Medical Science and Public health, Centro Sclerosi Multipla, University of Cagliari, 09126 Cagliari, Italy.

Marco Onofrj (M)

Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio di Chieti-Pescara, 66100 Chieti, Italy.

Franco Di Palma (F)

Department of Neurology, ASST Lariana Ospedale S. Anna, 22100 Como, Italy.

Francesco Patti (F)

Department of Medical and Surgical Sciences and Advanced Technologies 'G.F. Ingrassia', University of Catania, 95123 Catania, Italy.

Davide Maimone (D)

Department of Neurology, Ospedale Garibaldi Centro, 95123 Catania, Italy.

Paola Valentino (P)

Institute of Neurology, University 'Magna Graecia', 88100 Catanzaro, Italy.

Paolo Confalonieri (P)

Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico C. Besta, 20133 Milan, Italy.

Alessandra Protti (A)

Department of Neuroscience, Niguarda Hospital, 20162 Milano, Italy.

Patrizia Sola (P)

Department of Neurology, University of Modena and Reggio Emilia, 41125 Modena, Italy.

Giacomo Lus (G)

Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 81100 Naples, Italy.

Giorgia Teresa Maniscalco (GT)

Neurological Clinic and Multiple Sclerosis Center, A Cardarelli Hospital, 80131 Naples, Italy.

Vincenzo Brescia Morra (V)

Naples, Multiple Sclerosis Clinical Care and Research Center, Department of Neuroscience (NSRO), Federico II University, 80131 Naples, Italy.

Giuseppe Salemi (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy.

Franco Granella (F)

Unit of Neurosciences, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.

Ilaria Pesci (I)

Department of Neurology, Ospedale VAIO di Fidenza AUSL PR, 43036 Fidenza, Italy.

Roberto Bergamaschi (R)

Centro Sclerosi Multipla, IRCCS Fondazione Mondino, 27100 Pavia, Italy.

Umberto Aguglia (U)

Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.

Marika Vianello (M)

Unit of Neurology, Ca' Fancello Hospital, AULSS2, 31100 Treviso, Italy.

Marta Simone (M)

Child Neuropsychiatric Unit, Department of Biomedical Sciences and Human Oncology, University 'Aldo Moro' of Bari, 70124 Bari, Italy.

Vito Lepore (V)

Public Health Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.

Pietro Iaffaldano (P)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, 70124 Bari, Italy.

Massimo Filippi (M)

San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Neurology Unit and multiple sclerosis Center, IRCCS San Raffaele Scientific Institute; Neuroimaging Research Unit, Division of Neuroscience; Neurorehabilitation Unit and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.

Maria Trojano (M)

Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, 70124 Bari, Italy.

Maria Pia Amato (MP)

Department of NEUROFARBA, University of Florence, 50139 Florence, Italy.
Department of Neurology, IRCCS Fondazione Don Carlo Gnocchi, 50143 Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH